Best Life: ERX41 shows promise in fighting breast cancers

Published: Oct. 13, 2022 at 6:56 AM CDT
Email This Link
Share on Pinterest
Share on LinkedIn

SAN ANTONIO, Texas (Ivanhoe Newswire) – October is Breast Cancer Awareness Month. Triple-negative breast cancer is aggressive and if not caught early, has a five-year survival rate of only 12%.

Until now, doctors didn’t have much to fight the disease. But a new compound called ERX-41 is showing promise in knocking down triple negative, and other breast cancers.

“I was first diagnosed with cancer in July of 2018. The doctors examined both my breasts and felt a lump on my left,” said Lynnette Dawson.

Lynnette’s cancer has responded to chemo and radiation. She’s also had a double mastectomy. Lynnette has a form of cancer called HER2 that is hormonally driven. But triple-negative breast cancer has no hormone receptors and is very hard to treat.

“I think if it’s a grade two or grade three, 50% of them will not survive within five years,” said Professor OB/GYN at UT San Antonio, Ratna Vadlamudi, Ph.D.

Vadlamudi and his team tested 30,000 genes to find one to stop triple negative.

“What we found is ERX-41 binds to a new therapeutic target that is LipA,” said Vadlamudi.

Once ERX-441 binds to the LipA gene, then, the cancer senses defective cells and dies off.

Vadlamudi adds, “They accumulate in the lumen, and the lumen sends a signal that something is wrong—stop everything.”

Researchers have found a breakthrough in mice. Normal breast cells are not affected by ERX-41, and there is no toxicity to the patient. It’s also been effective against Lynnette’s subtype of cancer.

“HER2 positive is not the easiest. It likes to migrate to other parts of your body,” said Lynnette.

But if researchers have their way, there may be another potential option for women battling tough-to-treat breast cancers.

Vadlamudi says ERX-41 has been effective in knocking down cancer in mice in 60 days. He also says the compound is likely to be effective against other lethal cancers like pancreatic, ovarian and glioblastoma. Researchers expect human clinical trials to begin next year.

Contributors to this news report include Donna Parker, Producer; Bruce Maniscalco, Videographer; Roque Correa, Editor.

Click here to sign up for our newsletter!

Click here to report a spelling or grammar error. Please include the headline.